DURECT Corp

NASDAQ:DRRXUnited States

DURECT Corporation is a late-stage biopharmaceutical company. The Company is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. It also completed Alcohol-Associated Hepatitis (AHFIRM) Phase 2b study.

Contact Information

Headquarters

10240 Bubb RoadCUPERTINO, CA, United States 95014

Phone

408-777-1417

Fax

408-777-3577

Executives

Independent Chairman of the Board

Gail Maderis

President, Chief Executive Officer, Director

James Brown

Chief Financial Officer, Company Secretary

Timothy Papp

Chief Medical Officer

Norman Sussman

Independent Director

Mohammad Azab